Cediranib - AstraZeneca

Drug Profile

Cediranib - AstraZeneca

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; Mario Negri Institute for Pharmacological Research; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University Health Network; University of Manchester; University of Oxford
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Prostate cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 09 Mar 2018 AstraZeneca re-initiates phase-III clinical trials in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in the USA, Canada, South Korea and Japan (PO) (NCT02446600)
  • 01 Mar 2018 Phase-II clinical trials in Cervical cancer (Combination therapy, Late-stage disease, Metastatic disease, Maintenance therapy, Second-line therapy or greater) in United Kingdom (PO) (ISRCTN10841582)
  • 19 Jan 2018 AstraZeneca plans the phase II COMICE trial for advanced/recurrent Cervical cancer (Combination therapy; Second-line therapy or greater; Recurrent; Maintenance therapy; Late-stage disease) in United Kingdom (ISRCTN10841582)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top